Cytokine immunomodulation for the treatment of infectious diseases: lessons from primary immunodeficiencies

References

• Cheesman DF. Varro and the small beasts: a bimillennium for microbiologists. Nature 1964;203:911-12
   Google Scholar
• Thurston AJ. Of blood, inflammation and gunshot wounds: the history of the control of sepsis. Aust NZ J Surg 2000;70(12):855-61
   PubMedGoogle Scholar
• Drouhet E. Historical introduction: evolution of knowledge of the fungi and mycoses from Hippocrates to the twenty-first century, in Topley & Wilson’s microbiology and microbial infections. John Wiley & Sons, Ltd; 2010
   Google Scholar
• Espinell-Ingroff A. Medical mycology and training in the united states: a historical analysis (1894-1996) Springer - Kluwer Academic Publishers, Hoboken, NJ; 2003
   Google Scholar
• Author unlisted Miasmata and contagia. Lancet 1938;232(6018):1532-3
   Google Scholar
• Carter KC. Koch’s postulates in relation to the work of Jacob Henle and Edwin Klebs. Med Hist 1985;29(4):353-74
   PubMedGoogle Scholar
• Koch R. An address on the fight against tuberculosis in the light of the experience that has been gained in the successful combat of other infectious diseases. Br Med J 1901;2(2117):189-93
   PubMedGoogle Scholar
• Koch R. An address on bacteriological research. Br Med J 1890;2(1546):380-3
   PubMedGoogle Scholar
• Dunn PM. Ignac Semmelweis (1818 - 1865) of Budapest and the prevention of puerperal fever. Arch Dis Child Fetal Neonatal Ed 2005;90(4):F345-FF348
   Google Scholar
• Lister J. On the antiseptic principle in the practice of surgery. Br Med J 1867;2(351):246-8
   PubMedGoogle Scholar
• Sorgel F. The return of Ehrlich’s ’Therapia magna sterilisans’ and other Ehrlich concepts?. Series of papers honoring Paul Ehrlich on the occasion of his 150th birthday. Chemotherapy 2004;50(1):6-10
   PubMedGoogle Scholar
• Clutterbuck PW, Lovell R, Raistrick H. Studies in the biochemistry of micro-organisms: the formation from glucose by members of the Penicillium chrysogenum series of a pigment, an alkali-soluble protein and penicillin-the antibacterial substance of Fleming. Biochem J 1932;26(6):1907-18
   PubMedGoogle Scholar
• Evans AS. Pettenkofer revisited: the life and contributions of Max von Pettenkofer (1818-1901). Yale J Biol Med 1973;46(3):161-76
   PubMedGoogle Scholar
• Goodwin ME von Sholly AI. The frequent occurrence of meningococci in the nasal cavities of meningitis patients and of those in direct contact with them. Public Health Pap Rep 1905;31(Pt 2):21-34
   PubMedGoogle Scholar
• Rake G. Studies on meningococcus infection : VI. the carrier problem. J Exp Med 1934;59(5):553-76
   PubMedGoogle Scholar
• Mendelsohn JA. "Typhoid Mary" strikes again. The social and the scientific in the making of modern public health. Isis 1995;86(2):268-77
   PubMedGoogle Scholar
• von Sholly AI. A contribution to the statistics of the presence of diphtheria bacilli in apparently normal throats: report of 1,000 cases examined (1905-6). J Infect Dis 1907;4(3):337-46
   Google Scholar
• Stevenson LG. Exemplary disease: the typhoid pattern. J Hist Med Allied Sci 1982;37(2):159-81
   PubMedGoogle Scholar
• Edelman R, Levine MM. Summary of an international workshop on typhoid fever. Rev Infect Dis 1986. 8(3):329-49
   Google Scholar
• “Charles Nicolle - Nobel Lecture: investigations on Typhus”. Nobelprize.org. Nobel Media AB 2013. Web. 14 Jan 2014. www.nobelprize.org/nobel_prizes/medicine/laureates/1928/nicolle-lecture.html
   Google Scholar
• Garnham PCC. Charles Nicolle and in apparent infections. Am J Trop Med Hyg 1977;26(5):1101-4
   Google Scholar
• Garrod A. The Huxley Lecture on Diathesis. Br Med J 1927;2(3490):967-71
   PubMedGoogle Scholar
• MLA style: “Physiology or Medicine 1919 - Presentation Speech”. Nobelprize.org. Nobel Media AB 2013. www.nobelprize.org/nobel_prizes/medicine/laureates/1919/press.html [Last accessed 5 January 2014]
   Google Scholar
• Draper G, Allen G, Spock JC. Studies in human constitution: vi. clinical genetics. J Am Med Assoc 1929;92(26):2149-53
   Google Scholar
• Quartier P, Foray S, Casanova JL, et al. Enteroviral meningoencephalitis in X-linked agammaglobulinemia: intensive immunoglobulin therapy and sequential viral detection in cerebrospinal fluid by polymerase chain reaction. Pediatr Infect Dis J 2000;19(11):1106-8
   PubMedGoogle Scholar
• Ozsahin H, von Planta M, Muller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B. Blood 1998;92(8):2719-24
   PubMed Web of Science ®Google Scholar
• Sastry J, Kakakios A, Tugwell H, Shaw PJ. Allogeneic bone marrow transplantation with reduced intensity conditioning for chronic granulomatous disease complicated by invasive Aspergillus infection. Pediatr Blood Cancer 2006;47(3):327-9
   PubMedGoogle Scholar
• Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol 2013;50(3):198-206
   PubMed Web of Science ®Google Scholar
• Bonilla MA, Gillio AP, Ruggeiro M, et al. Effects of Recombinant Human Granulocyte Colony-Stimulating Factor on Neutropenia in Patients with Congenital Agranulocytosis. N Engl J Med 1989;320(24):1574-80
   Google Scholar
• Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990;75(5):1056-63
   PubMedGoogle Scholar
• Besner GE, Glick PL, Karp MP, et al. Recombinant human granulocyte colony-stimulating factor promotes wound healing in a patient with congenital neutropenia. J Pediatr Surg 1992;27(3):288-90. discussion 291
   PubMedGoogle Scholar
• Donini M, Fontana S, Savoldi G, et al. G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms. Blood 2007;109(11):4716-23
   PubMed Web of Science ®Google Scholar
• Kimura Y, Kuratsuji T, Itoh Y, et al. [Effect of rhG-CSF in the treatment of multiple hepatic abscesses in chronic granulomatous disease]. Rinsho Ketsueki 1990;31(9):1483-8
   PubMedGoogle Scholar
• Nakajima F, Takaya K, Hibi S, et al. [Recombinant human granulocyte-colony stimulating factor (rhG-CSF) treatment for spleen abscess and periostitis in a patient with chronic granulomatous disease]. Rinsho Ketsueki 1992;33(12):1869-74
   PubMedGoogle Scholar
• Fukuda T, Kitagawa S, Azuma E, et al. Treatment with granulocyte colony-stimulating factor for pneumonia in a patient with a variant form of X-linked chronic granulomatous disease. Eur J Haematol 1995;55(1):63-4
   PubMedGoogle Scholar
• Isotani H, Fukumoto Y, Kawamura H, et al. Treatment with rhG-CSF for osteomyelitis in a patient with p47-phox-deficient chronic granulomatous disease. Ann Hematol 1997;75(5-6):243-6
   PubMedGoogle Scholar
• Dotis J, Panagopoulou P, Filioti J, et al. Femoral osteomyelitis due to Aspergillus nidulans in a patient with chronic granulomatous disease. Infection 2003;31(2):121-4
   PubMedGoogle Scholar
• Pariyaprasert W, Pacharn P, Visitsunthorn N, et al. Successful treatment of disseminated BCG infection in a SCID patient with granulocyte colony stimulating factor. Asian Pac J Allergy Immunol 2008;26(1):71-5
   PubMedGoogle Scholar
• Imashuku S, Hibi S, Kataoka-Morimoto Y, et al. Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration. Br J Haematol 1995;89(1):188-90
   PubMedGoogle Scholar
• Kalra R, Dale D, Freedman M, et al. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood 1995;86(12):4579-86
   PubMed Web of Science ®Google Scholar
• Freedman MH. Safety of long-term administration of granulocyte colony-stimulating factor for severe chronic neutropenia. Curr Opin Hematol 1997;4(3):217-24
   PubMedGoogle Scholar
• Freedman MH, Bonilla MA, Fier C, et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. Blood 2000;96(2):429-36
   PubMedGoogle Scholar
• Tanaka T, Motoi N, Tsuchihashi Y, et al. Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. J Med Genet 2011;48(3):205-9
   PubMedGoogle Scholar
• Suzuki T, Maranda B, Sakagami T, et al. Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations. Eur Res J 2011;37(1):201-4
   PubMedGoogle Scholar
• Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 2008;205(12):2711-16
   PubMedGoogle Scholar
• Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008;205(12):2703-10
   PubMedGoogle Scholar
• Trapnell BC, Carey BC, Uchida K, Suzuki T. Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages. Curr Opin Immunol 2009;21(5):514-21
   PubMed Web of Science ®Google Scholar
• Seymour JF Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002;166(2):215-35
   PubMedGoogle Scholar
• Punatar AD, Kusne S, Blair JE, et al. Opportunistic infections in patients with pulmonary alveolar proteinosis. J Infect 2012;65(2):173-9
   PubMedGoogle Scholar
• Uchida K, Nakata K, Suzuki T, et al. Granulocyte/macrophage‚ Äìcolony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood 2009;113(11):2547-56
   PubMedGoogle Scholar
• Trapnell BC, Whitsett JA, Nakata K. Pulmonary Alveolar Proteinosis. N Engl J Med 2003;349(26):2527-39
   PubMed Web of Science ®Google Scholar
• Martino S, Ciocchini M, Marmont A, et al. Treatment of hepatic abscesses in chronic granulomatous disease with granulocyte-macrophage colony-stimulating factor. Clin Infect Dis 2000;30(1):222-3
   PubMedGoogle Scholar
• Holland SM. Chronic granulomatous disease. Clin Rev Allergy Immunol 2010;38(1):3-10
   PubMed Web of Science ®Google Scholar
• Lublin M, Bartlett DL, Danforth DN, et al. Hepatic abscess in patients with chronic granulomatous disease. Ann Surg 2002;235(3):383-91
   PubMed Web of Science ®Google Scholar
• Gavino C, Cotter A, Lichtenstein D, et al. CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy. Clin Infect Dis 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N Engl J Med 2009;361(18):1727-35
   PubMed Web of Science ®Google Scholar
• Drewniak A, Gazendam RP, Tool AT, et al. Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood 2013;121(13):2385-92
   PubMed Web of Science ®Google Scholar
• Lanternier F, Pathan S, Vincent QB, et al. Deep dermatophytosis and inherited CARD9 deficiency. N Engl J Med 2013;369(18):1704-14
   PubMed Web of Science ®Google Scholar
• Lotze MT, Matory YL, Ettinghausen SE, et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol 1985;135(4):2865-75
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C, Mayer L, Sapira E, Mendelsohn L. Restoration of immunoglobulin secretion in vitro in common variable immunodeficiency by in vivo treatment with polyethylene glycol-conjugated human recombinant interleukin-2. Clin Immunol Immunopathol 1992;64(1):46-56
   PubMedGoogle Scholar
• Cunningham-Rundles C, Bodian C, Ochs HD, et al. Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency. Clin Immunol 2001;100(2):181-90
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C, Kazbay K, Zhou Z, Mayer L. Immunologic effects of low-dose polyethylene glycol-conjugated recombinant human interleukin-2 in common variable immunodeficiency. J Interferon Cytokine Res 1995;15(3):269-76
   PubMedGoogle Scholar
• Cunningham-Rundles C, Kazbay K, Hassett J, et al. Brief report: enhanced humoral immunity in common variable immunodeficiency after long-term treatment with polyethylene glycol-conjugated interleukin-2. N Engl J Med 1994;331(14):918-21
   PubMedGoogle Scholar
• Rump JA, Jahreis A, Schlesier M, et al. A double-blind, placebo-controlled, crossover therapy study with natural human IL-2 (nhuIL-2) in combination with regular intravenous gammaglobulin (IVIG) infusions in 10 patients with common variable immunodeficiency (CVID). Clin Exp Immunol 1997;110(2):167-73
   PubMedGoogle Scholar
• Yilmaz-Demirdag Y, Wilson B, Lowery-Nordberg M, et al. Interleukin-2 treatment for persistent cryptococcal meningitis in a child with idiopathic CD4(+) T lymphocytopenia. Allergy Asthma Proc 2008;29(4):421-4
   PubMedGoogle Scholar
• Centers for Disease Control (CDC). Unexplained CD4+ T-lymphocyte depletion in persons without evident HIV infection--United States. MMWR Morb Mortal Wkly Rep 1992;41(30):541-5
   PubMedGoogle Scholar
• Kuijpers TW, IJspeert H, van Leeuwen EMM, et al. Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations. Blood 2011;117(22):5892-6
   PubMed Web of Science ®Google Scholar
• Gorska MM Alam R. A mutation in the human Uncoordinated 119 gene impairs TCR signaling and is associated with CD4 lymphopenia. Blood 2012;119(6):1399-406
   PubMedGoogle Scholar
• Hauck F, Randriamampita C, Martin E, et al. Primary T-cell immunodeficiency with immunodysregulation caused by autosomal recessive LCK deficiency. J Allergy Clin Immunol 2012;130(5):1144-52. e11
   PubMedGoogle Scholar
• Zonios DI, Falloon J, Huang CY, et al. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore) 2007;86(2):78-92
   PubMed Web of Science ®Google Scholar
• Azuma H, Sakata H, Saijyou M, Okuno A. Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome. Eur J Pediatr 1993;152(12):998-1000
   PubMedGoogle Scholar
• Albert MH, Notarangelo LD, Ochs HD. Clinical spectrum, pathophysiology and treatment of the Wiskott-Aldrich syndrome. Curr Opin Hematol 2011;18(1):42-8
   PubMed Web of Science ®Google Scholar
• Moulding DA, Record J, Malinova D, Thrasher AJ. Actin cytoskeletal defects in immunodeficiency. Immunol Rev 2013;256(1):282-99
   PubMedGoogle Scholar
• Azuma H, Oshima M, Ito K, et al. Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy. Eur J Pediatr 2000;159(8):633-4
   PubMedGoogle Scholar
• Warnatz K, Draeger R, Schlesier M, Peter H-H. Successful IL-2 therapy for relapsing herpes zoster infection in a patient with idiopathic CD4+ T lymphocytopenia. Immunobiology 2000;202(2):204-11
   PubMedGoogle Scholar
• Cunningham-Rundles C, Murray HW, Smith JP. Treatment of idiopathic CD4 T lymphocytopenia with IL-2. Clin Exp Immunol 1999;116(2):322-5
   PubMedGoogle Scholar
• Trojan T, Collins R, Khan DA. Safety and efficacy of treatment using interleukin-2 in a patient with idiopathic CD4(+) lymphopenia and Mycobacterium avium-intracellulare. Clin Exp Immunol 2009;156(3):440-5
   PubMedGoogle Scholar
• Sternfeld T, Nigg A, Belohradsky BH, Bogner JR. Treatment of relapsing Mycobacterium avium infection with interferon-gamma and interleukin-2 in an HIV-negative patient with low CD4 syndrome. Int J Infect Dis 2010;14(Suppl 3):e198-201
   Google Scholar
• Amin A White RL Jr. High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies? Oncology (Williston Park) 2013;27(7):680-91
   PubMedGoogle Scholar
• Smith KA. Low-dose daily interleukin-2 immunotherapy: accelerating immune restoration and expanding HIV-specific T-cell immunity without toxicity. AIDS. 2001;15(Suppl 2):S28-35
   Google Scholar
• Patel A, Patel J, Ikwuagwu J. A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 2010;65(12):2697-8
   PubMed Web of Science ®Google Scholar
• Khanna N, Elzi L, Mueller NJ, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 2009;48(10):1459-66
   PubMed Web of Science ®Google Scholar
• Bellizzi A, Anzivino E, Rodio DM, et al. New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy. Clin Dev Immunol 2013;2013:839719
   PubMedGoogle Scholar
• Patel A, Patel J, Ikwuagwu J. Treatment of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia. J Antimicrob Chemother 2010;65(12):2489-92
   PubMedGoogle Scholar
• Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and Characterization of Mefloquine Efficacy against JC Virus In Vitro. Antimicrob Agents Chemother 2009;53(5):1840-9
   PubMed Web of Science ®Google Scholar
• Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009;119(4):997-1007
   PubMed Web of Science ®Google Scholar
• Sereti I, Dunham RM, Spritzler J, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009;113(25):6304-14
   PubMedGoogle Scholar
• Sportes C, Babb RR, Krumlauf MC, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010;16(2):727-35
   PubMed Web of Science ®Google Scholar
• Perales MA, Goldberg JD, Yuan J, et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 2012;120(24):4882-91
   PubMedGoogle Scholar
• Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 2007;282(28):20047-51
   PubMed Web of Science ®Google Scholar
• Masci P, Bukowski RM, Patten PA, et al. New and modified interferon alfas: preclinical and clinical data. Curr Oncol Rep 2003;5(2):108-13
   PubMedGoogle Scholar
• Ramoz N, Rueda LA, Bouadjar B, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002;32(4):579-81
   PubMedGoogle Scholar
• Crequer A, Troeger A, Patin E, et al. Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest 2012;122(9):3239-47
   PubMedGoogle Scholar
• Crequer A, Picard C, Patin E, et al. Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. PLoS One 2012;7(8):e44010
   Google Scholar
• Stetson CL, Rapini RP, Tyring SK, Kimbrough RC. CD4+ T lymphocytopenia with disseminated HPV. J Cutan Pathol 2002;29(8):502-5
   PubMedGoogle Scholar
• Pasic S, Minic P, Dzudovic S, et al. Idiopathic CD4+ lymphocytopenia and juvenile laryngeal papillomatosis. Pediatr Pulmonol 2005;39(3):281-3
   PubMedGoogle Scholar
• Rossi G, Tucci A, Cariani E, et al. Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to the immune status. Blood 1997;90(3):1309-14
   PubMedGoogle Scholar
• Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331(24):1607-11
   PubMed Web of Science ®Google Scholar
• Chapel HM, Christie JM, Peach V, Chapman RW. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol 2001;99(3):320-4
   PubMed Web of Science ®Google Scholar
• Hourihane J, Hodges E, Smith J, et al. Interferon alpha treatment of molluscum contagiosum in immunodeficiency. Arch Dis Child 1999;80(1):77-9
   PubMedGoogle Scholar
• Böhm M, Luger TA, Bonsmann G. Disseminated giant molluscum contagiosum in a patient with idiopathic CD4+ lymphocytopenia. Successful eradication with systemic interferon. Dermatology 2008;217(3):196-8
   PubMedGoogle Scholar
• Kilic SS, Kilicbay F. Interferon-alpha treatment of molluscum contagiosum in a patient with hyperimmunoglobulin E syndrome. Pediatrics 2006;117(6):e1253-5
   PubMedGoogle Scholar
• Yong PF, Freeman AF, Engelhardt KR, et al. An update on the hyper-IgE syndromes. Arthritis Res Ther 2012;14(6):228
   PubMedGoogle Scholar
• Minegishi Y, Saito M, Morio T, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 2006;25(5):745-55
   PubMed Web of Science ®Google Scholar
• Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr 2012;160(6):1055-7
   PubMed Web of Science ®Google Scholar
• Chen X, Anstey AV, Bugert JJ. Molluscum contagiosum virus infection. Lancet Infect Dis 2013;13(10):877-88
   PubMed Web of Science ®Google Scholar
• Ward CM, Jyonouchi H, Kotenko SV, et al. Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency. Eur J Pediatr 2007;166(9):981-5
   PubMedGoogle Scholar
• Horwitz ME, Uzel G, Linton GF, et al. Persistent Mycobacterium avium infection following nonmyeloablative allogeneic peripheral blood stem cell transplantation for interferon-gamma receptor-1 deficiency. Blood 2003;102(7):2692-4
   PubMedGoogle Scholar
• Roesler J, Horwitz ME, Picard C, et al. Hematopoietic stem cell transplantation for complete IFN-gamma receptor 1 deficiency: a multi-institutional survey. J Pediatr 2004;145(6):806-12
   PubMed Web of Science ®Google Scholar
• Piehler J, Thomas C, Garcia KC, Schreiber G. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol Rev 2012;250(1):317-34
   PubMed Web of Science ®Google Scholar
• Dupuis S, Jouanguy E, Al-Hajjar S, et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet 2003;33(3):388-91
   PubMed Web of Science ®Google Scholar
• Bax HI, Freeman AF, Ding L, et al. Interferon alpha treatment of patients with impaired interferon gamma signaling. J Clin Immunol 2013;33(5):991-1001
   PubMed Web of Science ®Google Scholar
• Zdilar D, Franco-Bronson K, Buchler N, et al. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31(6):1207-11
   PubMed Web of Science ®Google Scholar
• Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One 2013;8(2):e55364
   Web of Science ®Google Scholar
• Plosker GL. Interferon-beta-1b: a review of its use in multiple sclerosis. CNS Drugs 2011;25(1):67-88
   PubMed Web of Science ®Google Scholar
• von der Wense A, Herrmann B, Deppermann R, et al. [Intrathecal interferon therapy in chronic echovirus meningoencephalitis in Bruton type agammaglobulinemia]. Klin Padiatr 1998;210(2):51-5
   PubMedGoogle Scholar
• Bekisz J, Schmeisser H, Hernandez J, et al. Human interferons alpha, beta and omega. Growth Factors 2004;22(4):243-51
   PubMed Web of Science ®Google Scholar
• A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The international chronic granulomatous disease Cooperative Study Group. N Engl J Med 1991;324(8):509-16
   PubMed Web of Science ®Google Scholar
• Reeves JD, August CS, Humbert JR, Weston WL. Host defense in infantile osteopetrosis. Pediatrics 1979;64(2):202-6
   PubMedGoogle Scholar
• Yang S, Ries WL, Key LL Jr. Superoxide generation in transformed B-lymphocytes from patients with severe, malignant osteopetrosis. Mol Cell Biochem 1999;199(1-2):15-24
   PubMedGoogle Scholar
• Key LL Jr, Rodriguiz RM, Willi SM, et al. Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med 1995;332(24):1594-9
   PubMed Web of Science ®Google Scholar
• Shankar L, Gerritsen EJ, Key LL Jr. Osteopetrosis: pathogenesis and rationale for the use of interferon-gamma-1b. BioDrugs 1997;7(1):23-9
   PubMedGoogle Scholar
• Hague RA, Eastham EJ, Lee RE, Cant AJ. Resolution of hepatic abscess after interferon gamma in chronic granulomatous disease. Arch Dis Child 1993;69(4):443-5
   PubMed Web of Science ®Google Scholar
• Malmvall BE, Follin P. Successful interferon-gamma therapy in a chronic granulomatous disease (CGD) patient suffering from Staphylococcus aureus hepatic abscess and invasive Candida albicans infection. Scand J Infect Dis 1993;25(1):61-6
   PubMedGoogle Scholar
• Lekstrom-Himes JA, Holland SM, DeCarlo ES, et al. Treatment with intralesional granulocyte instillations and interferon-gamma for a patient with chronic granulomatous disease and multiple hepatic abscesses. Clin Infect Dis 1994;19(4):770-3
   PubMed Web of Science ®Google Scholar
• Conte D, Fraquelli M, Capsoni F, et al. Effectiveness of IFN-gamma for liver abscesses in chronic granulomatous disease. J Interferon Cytokine Res 1999;19(7):705-10
   PubMed Web of Science ®Google Scholar
• Johnston RB, Newman SL. Chronic granulomatous disease. Pediatr Clin North Am 1977;24(2):365-76
   PubMed Web of Science ®Google Scholar
• Altare F, Lammas D, Revy P, et al. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guerin and Salmonella enteritidis disseminated infection. J Clin Invest 1998;102(12):2035-40
   PubMed Web of Science ®Google Scholar
• Ma JS, Chen PY, Lau YJ, Chi CS. Brain abscess caused by Salmonella enterica subspecies houtenae in a patient with chronic granulomatous disease. J Microbiol Immunol Infect 2003;36(4):282-4
   PubMedGoogle Scholar
• Prando C, Samarina A, Bustamante J, et al. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore) 2013;92(2):109-22
   PubMed Web of Science ®Google Scholar
• Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79(3):155-69
   PubMed Web of Science ®Google Scholar
• van den Berg JM, van Koppen E, Ahlin A, et al. Chronic granulomatous disease: the European experience. PLoS One 2009;4(4):e5234
   PubMed Web of Science ®Google Scholar
• Cohen MS, Isturiz RE, Malech HL, et al. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med 1981;71(1):59-66
   PubMedGoogle Scholar
• Vinh DC, Shea YR, Sugui JA, et al. Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis 2009;49(1):102-11
   PubMedGoogle Scholar
• Gallin JI, Zarember K. Lessons about the pathogenesis and management of aspergillosis from studies in chronic granulomatous disease. Trans Am Clin Climatol Assoc 2007;118:175-85
   PubMedGoogle Scholar
• Bernhisel-Broadbent J, Camargo EE, Jaffe HS, Lederman HM. Recombinant human interferon-gamma as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease. J Infect Dis 1991;163(4):908-11
   PubMedGoogle Scholar
• Pasic S, Abinun M, Pistignjat B, et al. Aspergillus osteomyelitis in chronic granulomatous disease: treatment with recombinant gamma-interferon and itraconazole. Pediatr Infect Dis J 1996;15(9):833-4
   PubMed Web of Science ®Google Scholar
• Tsumura N, Akasu Y, Yamane H, et al. Aspergillus osteomyelitis in a child who has p67-phox-deficient chronic granulomatous disease. Kurume Med J 1999;46(1):87-90
   PubMedGoogle Scholar
• Saulsbury FT. Successful treatment of aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease. Clin Infect Dis 2001;32(10):E137-9
   Google Scholar
• Mamishi S, Zomorodian K, Saadat F, et al. A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin B and INF-gamma. Ann Clin Microbiol Antimicrob 2005;4:4
   PubMedGoogle Scholar
• Patiroglu T, Unal E, Yikilmaz A, et al. Atypical presentation of chronic granulomatous disease in an adolescent boy with frontal lobe located Aspergillus abscess mimicking intracranial tumor. Childs Nerv Syst 2010;26(2):149-54
   PubMedGoogle Scholar
• Phillips P, Forbes JC, Speert DP. Disseminated infection with Pseudallescheria boydii in a patient with chronic granulomatous disease: response to gamma-interferon plus antifungal chemotherapy. Pediatr Infect Dis J 1991;10(7):536-9
   PubMedGoogle Scholar
• Cohen-Abbo A, Edwards KM. Multifocal osteomyelitis caused by Paecilomyces varioti in a patient with chronic granulomatous disease. Infection 1995;23(1):55-7
   PubMed Web of Science ®Google Scholar
• Netea MG, Brouwer AE, Hoogendoorn EH, et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis 2004;39(9):e83-7
   PubMed Web of Science ®Google Scholar
• Rezai MS, Khotael G, Kheirkhah M, et al. Cryptococcosis and deficiency of interleukin12r. Pediatr Infect Dis J 2008;27(7):673
   PubMedGoogle Scholar
• Filipe-Santos O, Bustamante J, Haverkamp MH, et al. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med 2006;203(7):1745-59
   PubMed Web of Science ®Google Scholar
• Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004;364(9451):2113-21
   PubMed Web of Science ®Google Scholar
• Al-Muhsen S, Casanova JL. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol 2008;122(6):1043-51. quiz 1052-3
   PubMed Web of Science ®Google Scholar
• Kong XF, Vogt G, Itan Y, et al. Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease. Hum Mol Genet 2013;22(4):769-81
   PubMed Web of Science ®Google Scholar
• Holland SM, Eisenstein EM, Kuhns DB, et al. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994;330(19):1348-55
   PubMedGoogle Scholar
• Ulrichs T, Fieschi C, Nevicka E, et al. Variable outcome of experimental interferon-gamma therapy of disseminated Bacillus Calmette-Guerin infection in two unrelated interleukin-12Rbeta1-deficient Slovakian children. Eur J Pediatr 2005;164(3):166-72
   PubMedGoogle Scholar
• Rosenzweig SD, Yancoski J, Bernasconi A, et al. Thirteen years of culture-positive M. bovis-BCG infection in an IL-12Rbeta1 deficient patient: treatment and outcome. J Infect 2006;52(3):e69-72
   Google Scholar
• Alangari AA, Al-Zamil F, Al-Mazrou A, et al. Treatment of disseminated mycobacterial infection with high-dose IFN-gamma in a patient with IL-12Rbeta1 deficiency. Clin Dev Immunol 2011;2011:691956
   PubMedGoogle Scholar
• Jouanguy E, Lamhamedi-Cherradi S, Lammas D, et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat Genet 1999;21(4):370-8
   PubMed Web of Science ®Google Scholar
• Waibel KH, Regis DP, Uzel G, et al. Fever and leg pain in a 42-month-old. Ann Allergy Asthma Immunol 2002;89(3):239-43
   PubMedGoogle Scholar
• Smyth AE, Jackson P, Lammas D, et al. Differential response to interferon-gamma therapy in a family with dominant negative partial interferon-gamma receptor1 deficiency. Eur J Pediatr 2006;165(1):71-2
   PubMedGoogle Scholar
• Vinh DC, Masannat F, Dzioba RB, et al. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency. Clin Infect Dis 2009;49(6):e62-5
   Google Scholar
• Döffinger R, Jouanguy E, Dupuis S, et al. Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guerin and Mycobacterium abscessus infection. J Infect Dis 2000;181(1):379-84
   PubMed Web of Science ®Google Scholar
• Marchand I, Mahe E, Clerici T, et al. [Disseminated BCG infection revealing X-linked severe combined immunodeficiency]. Ann Dermatol Venereol 2008;135(8-9):587-90
   PubMedGoogle Scholar
• Kelly BT, Tam JS, Verbsky JW, Routes JM. Screening for severe combined immunodeficiency in neonates. Clin Epidemiol 2013;5:363-9
   PubMedGoogle Scholar
• Bogunovic D, Byun M, Durfee LA, et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science 2012;337(6102):1684-8
   PubMed Web of Science ®Google Scholar
• Hambleton S, Salem S, Bustamante J, et al. IRF8 Mutations and Human Dendritic-Cell Immunodeficiency. N Engl J Med 2011;365(2):127-38
   PubMed Web of Science ®Google Scholar
• Vinh DC, Patel SY, Uzel G, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010;115(8):1519-29
   PubMed Web of Science ®Google Scholar
• Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011;118(10):2653-5
   PubMed Web of Science ®Google Scholar
• Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011;118(10):2656-8
   PubMed Web of Science ®Google Scholar
• Marciano BE, Wesley R, De Carlo ES, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 2004;39(5):692-9
   PubMed Web of Science ®Google Scholar
• ACTIMMUNE® (Interferon gamma-1b) Full Prescribing Information. Vidara Therapeutics Inc; Roswell, GA, USA: 2013
   Google Scholar
• Fieschi C, Dupuis S, Picard C, et al. High levels of interferon gamma in the plasma of children with complete interferon gamma receptor deficiency. Pediatrics 2001;107(4):E48
   PubMed Web of Science ®Google Scholar
• Hailu A, van der Poll T, Berhe N, Kager PA. Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg 2004;71(5):561-7
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva C, et al. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. Drugs R D 2004;5(5):271-80
   PubMedGoogle Scholar
• Besredka A. Antivirus therapy in infectious diseases. Proc R Soc Med 1929;22(12):1579-98
   PubMedGoogle Scholar
• Zinsser H. Immunity-general and local. Bull N Y Acad Med 1930;6(11):709-33
   PubMedGoogle Scholar
• Sancho-Shimizu V, Perez de Diego R, Jouanguy E, et al. Inborn errors of anti-viral interferon immunity in humans. Curr Opin Virol 2011;1(6):487-96
   PubMedGoogle Scholar
• Vinh DC. Insights into human antifungal immunity from primary immunodeficiencies. Lancet Infect Dis 2011;11(10):780-92
   PubMedGoogle Scholar
• Lanternier F, Cypowyj S, Picard C, et al. Primary immunodeficiencies underlying fungal infections. Curr Opin Pediatr 2013;25(6):736-47
   PubMed Web of Science ®Google Scholar
• O’Connell ML, Birkenkamp KE, Kleiner DE, et al. Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease. Chest 2012;141(5):1203-9
   PubMedGoogle Scholar
• Bustamante J, Arias AA, Vogt G, et al. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol 2011;12(3):213-21
   PubMed Web of Science ®Google Scholar
• Wallis RS. Lack of a therapeutic role for interferon gamma in patients with tuberculosis. J Infect Dis 2014;209(4):627-8
   PubMedGoogle Scholar
• Morner KAH. The nobel lectures in immunology lecture for the nobel prize for physiology or medicine 1908. Scand J Immunol 1990;31(1):2-3
   Google Scholar
• Duplessis CA, Tilley D, Bavaro M, et al. Two cases illustrating successful adjunctive interferon-gamma immunotherapy in refractory disseminated coccidioidomycosis. J Infect 2011;63(3):223-8
   PubMedGoogle Scholar
• Kuberski TT, Servi RJ, Rubin PJ. Successful treatment of a critically ill patient with disseminated coccidioidomycosis, using adjunctive interferon-gamma. Clin Infect Dis 2004;38(6):910-12
   PubMed Web of Science ®Google Scholar
• Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010;137(1):21-30
   PubMed Web of Science ®Google Scholar
• Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol 2013;33(Suppl 2):S90-4
   PubMedGoogle Scholar
• Schmid ST, Koepke J, Dresel M, et al. The effects of weekly augmentation therapy in patients with PiZZ alpha1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2012;7:687-96
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Aiuti A, Porta F, et al. How I treat ADA deficiency. Blood 2009;114(17):3524-32
   PubMed Web of Science ®Google Scholar
• Markert ML, Devlin BH, McCarthy EA. Thymus transplantation. Clin Immunol 2010;135(2):236-46
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progress, pitfalls and prospects. Gene 2013;525(2):174-81
   PubMed Web of Science ®Google Scholar
• Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med 2014;6(227):227ra33
   PubMed Web of Science ®Google Scholar
• Venkateshiah SB, Yan TD, Bonfield TL, et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 2006;130(1):227-37
   PubMedGoogle Scholar
• Pahwa R, Chatila T, Pahwa S, et al. Recombinant interleukin 2 therapy in severe combined immunodeficiency disease. Proc Natl Acad Sci USA 1989;86(13):5069-73
   PubMedGoogle Scholar
• Orange JS, Brodeur SR, Jain A, et al. Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest 2002;109(11):1501-9
   PubMedGoogle Scholar
• Mizesko MC, Banerjee PP, Monaco-Shawver L, et al. Defective actin accumulation impairs human natural killer cell function in patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol 2013;131(3):840-8
   PubMedGoogle Scholar
• Mace EM, Hsu AP, Monaco-Shawver L, et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56bright subset. Blood 2013;121(14):2669-77
   PubMedGoogle Scholar
• Ezekowitz RA, Orkin SH, Newburger PE. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin Invest 1987;80(4):1009-16
   PubMedGoogle Scholar
• Ezekowitz RA, Dinauer MC, Jaffe HS, et al. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988;319(3):146-51
   PubMed Web of Science ®Google Scholar
• Key LL Jr, Ries WL, Rodriguiz RM, Hatcher HC. Recombinant human interferon gamma therapy for osteopetrosis. J Pediatr 1992;121(1):119-24
   PubMedGoogle Scholar
• Stark Z, Savarirayan R. Osteopetrosis. Orphanet J Rare Dis 2009;4:5
   PubMed Web of Science ®Google Scholar
• Blanchet-Bardon C, Puissant A, Lutzner M, et al. Interferon treatment of skin cancer in patients with epidermodysplasia verruciformis. Lancet 1981;1(8214):274
   PubMedGoogle Scholar
• Lutzner MA, Blanchet-Bardon C, Orth G. Clinical observations, virologic studies, and treatment trials in patients with epidermodysplasia verruciformis, a disease induced by specific human papillomaviruses. J Invest Dermatol 1984;83(1 Suppl):18s-25s
   PubMed Web of Science ®Google Scholar
• Androphy EJ, Dvoretzky I, Maluish AE, et al. Response of warts in epidermodysplasia verruciformis to treatment with systemic and intralesional alpha interferon. J Am Acad Dermatol 1984;11(2 Pt 1):197-202
   PubMedGoogle Scholar
• Toraldo R, D’Avanzo M, Tolone C, et al. Effect of interferon-alpha therapy in a patient with common variable immunodeficiency and chronic Epstein-Barr virus infection. Pediatr Hematol Oncol 1995;12(5):489-93
   PubMed Web of Science ®Google Scholar
• Anadolu R, Oskay T, Erdem C, et al. Treatment of epidermodysplasia verruciformis with a combination of acitretin and interferon alfa-2a. J Am Acad Dermatol 2001;45(2):296-9
   PubMedGoogle Scholar
• Gubinelli E, Posteraro P, Cocuroccia B, Girolomoni G. Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin. J Dermatolog Treat 2003;14(3):184-8
   PubMedGoogle Scholar
• Baskan EB, Tunali S, Adim SB, et al. A case of epidermodysplasia verruciformis associated with squamous cell carcinoma and Bowen’s disease: a therapeutic challenge. J Dermatolog Treat 2006;17(3):179-83
   PubMed Web of Science ®Google Scholar
• Silva CS, Pires MC, de Oliveira Ramos R, Sittart JAS. Epidermodysplasia verruciformis: combined treatment with acitretin and interferon alpha-2a. An Bras Dermatol 2006;81(6):592-4
   Google Scholar
• Strnad-Trojan N, Linde R, Reichenbach J, et al. Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome. Eur J Pediatr 2006;165(5):348-50
   PubMedGoogle Scholar
• Fischer LA, Norgaard A, Permin H, et al. Multiple flat warts associated with idiopathic CD4-positive T lymphocytopenia. J Am Acad Dermatol 2008;58(2 Suppl):S37-8
   Google Scholar
• Levin M, Newport MJ, D’Souza S, et al. Familial disseminated atypical mycobacterial infection in childhood: a human mycobacterial susceptibility gene? Lancet 1995;345(8942):79-83
   PubMedGoogle Scholar
• Metin A, Uysal G, Guven A, et al. Tuberculous brain abscess in a patient with hyper IgE syndrome. Pediatr Int 2004;46(1):97-100
   PubMedGoogle Scholar
• Remiszewski P, Roszkowska-Sliz B, Winek J, et al. Disseminated Mycobacterium avium infection in a 20-year-old female with partial recessive IFNgammaR1 deficiency. Respiration 2006;73(3):375-8
   PubMedGoogle Scholar
• Bermudez LE, Kemper CA, Deresinski SC. Dysfunctional monocytes from a patient with disseminated Mycobacterium kansasii infection are activated in vitro and in vivo by GM-CSF. Biotherapy 1994;8(2):135-42
   PubMedGoogle Scholar
• Flomenberg N, Welte K, Mertelsmann R, et al. Immunologic effects of interleukin 2 in primary immunodeficiency diseases. J Immunol 1983;130(6):2644-50
   PubMedGoogle Scholar
• Doi S, Saiki O, Hara T, et al. Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient. Eur J Pediatr 1989;148(7):630-3
   PubMedGoogle Scholar
• Pahwa S, Kirkpatrick D, Ching C, et al. Persistent cytomegalovirus infection: association with profound immunodeficiency and treatment with interferon. Clin Immunol Immunopathol 1983;28(1):77-89
   PubMedGoogle Scholar
• Mayumi M, Yamaoka K, Tsutsui T, et al. Selective immunoglobulin M deficiency associated with disseminated molluscum contagiosum. Eur J Pediatr 1986;145(1-2):99-103
   PubMedGoogle Scholar
• Kondoh H, Kobayashi K, Sugio Y, Hayashi T. Successful treatment of echovirus meningoencephalitis in sex-linked agammaglobulinaemia by intrathecal and intravenous injection of high titre gammaglobulin. Eur J Pediatr 1987;146(6):610-12
   PubMedGoogle Scholar
• Roberton DM, Jack I, Joshi W, et al. Failure of intraventricular gammaglobulin and alpha interferon for persistent encephalitis in congenital hypogammaglobulinaemia. Arch Dis Child 1988;63(8):948-52
   PubMedGoogle Scholar
• Okano M, Pirruccello SJ, Grierson HL, et al. Immunovirological studies of fatal infectious mononucleosis in a patient with X-linked lymphoproliferative syndrome treated with intravenous immunoglobulin and interferon-alpha. Clin Immunol Immunopathol 1990;54(3):410-18
   PubMedGoogle Scholar
• Ozarmagan G, Didem Yazganoglu K, Agacfidan A. Hyper-IgE syndrome with widespread premalign oral papillomas treated with interferon alpha2b. Acta Derm Venereol 2005;85(5):433-5
   PubMedGoogle Scholar
• Niehues T, Reichenbach J, Neubert J, et al. Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J Allergy Clin Immunol 2004;114(6):1456-62
   PubMedGoogle Scholar
• Asadullah K, Renz H, Docke WD, et al. Verrucosis of hands and feet in a patient with combined immune deficiency. J Am Acad Dermatol 1997;36(5 Pt 2):850-2
   PubMedGoogle Scholar
• Okano M, Thiele GM, Kobayashi RH, et al. Interferon-gamma in a family with X-linked lymphoproliferative syndrome with acute Epstein-Barr virus infection. J Clin Immunol 1989;9(1):48-54
   PubMedGoogle Scholar
• Sanal O, Morgan G, Gocmen A, et al. Isolated cutaneous response to granulocyte-monocyte colony stimulating factor in fatal idiopathic disseminated Bacillus-Calmette-Guerin infection. Eur J Pediatr 2000;159(3):149-52
   PubMedGoogle Scholar
• Tobin E, Rohwedder A, Holland SM, et al. Recurrent ‘sterile’ verrucous cyst abscesses and epidermodysplasia verruciformis-like eruption associated with idiopathic CD4 lymphopenia. Br J Dermatol 2003;149(3):627-33
   PubMedGoogle Scholar